Vascular Biogenics (NASDAQ:VBLT) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13), Morningstar.com reports. Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 31.69%.
Shares of NASDAQ VBLT opened at $1.25 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.35 and a quick ratio of 8.35. Vascular Biogenics has a 52 week low of $0.60 and a 52 week high of $1.90. The company has a 50-day moving average of $1.30. The firm has a market capitalization of $45.21 million, a PE ratio of -2.02 and a beta of -0.33.
Several research firms have recently commented on VBLT. ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Chardan Capital restated a “hold” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research note on Tuesday. CIBC assumed coverage on shares of Vascular Biogenics in a research note on Thursday, June 27th. They issued an “outperform” rating for the company. Zacks Investment Research cut shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a research note on Thursday, May 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Vascular Biogenics in a research note on Thursday, May 16th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Vascular Biogenics has a consensus rating of “Buy” and an average price target of $2.38.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Article: Stock Symbols and CUSIP Explained
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.